BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schwimmer JB, Johnson JS, Angeles JE, Behling C, Belt PH, Borecki I, Bross C, Durelle J, Goyal NP, Hamilton G, Holtz ML, Lavine JE, Mitreva M, Newton KP, Pan A, Simpson PM, Sirlin CB, Sodergren E, Tyagi R, Yates KP, Weinstock GM, Salzman NH. Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019;157:1109-22. [PMID: 31255652 DOI: 10.1053/j.gastro.2019.06.028] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 22.7] [Reference Citation Analysis]
Number Citing Articles
1 Yang M, Yin Y, Wang F, Zhang H, Ma X, Yin Y, Tan B, Chen J. Supplementation With Lycium barbarum Polysaccharides Reduce Obesity in High-Fat Diet-Fed Mice by Modulation of Gut Microbiota. Front Microbiol 2021;12:719967. [PMID: 34512598 DOI: 10.3389/fmicb.2021.719967] [Reference Citation Analysis]
2 Singh M, Hardin SJ, George AK, Eyob W, Stanisic D, Pushpakumar S, Tyagi SC. Epigenetics, 1-Carbon Metabolism, and Homocysteine During Dysbiosis. Front Physiol 2020;11:617953. [PMID: 33708132 DOI: 10.3389/fphys.2020.617953] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhang Y, Jiang W, Xu J, Wu N, Wang Y, Lin T, Liu Y, Liu Y. E. coli NF73-1 Isolated From NASH Patients Aggravates NAFLD in Mice by Translocating Into the Liver and Stimulating M1 Polarization. Front Cell Infect Microbiol 2020;10:535940. [PMID: 33363046 DOI: 10.3389/fcimb.2020.535940] [Reference Citation Analysis]
4 de Conti A, Tryndyak V, Willett RA, Borowa-Mazgaj B, Watson A, Patton R, Khare S, Muskhelishvili L, Olson GR, Avigan MI, Cerniglia CE, Ross SA, Sanyal AJ, Beland FA, Rusyn I, Pogribny IP. Characterization of the variability in the extent of nonalcoholic fatty liver induced by a high-fat diet in the genetically diverse Collaborative Cross mouse model. FASEB J 2020;34:7773-85. [PMID: 32304142 DOI: 10.1096/fj.202000194R] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Watanabe T, Tsuchiya A, Takeuchi S, Nojiri S, Yoshida T, Ogawa M, Itoh M, Takamura M, Suganami T, Ogawa Y, Terai S. Development of a non-alcoholic steatohepatitis model with rapid accumulation of fibrosis, and its treatment using mesenchymal stem cells and their small extracellular vesicles. Regen Ther 2020;14:252-61. [PMID: 32455155 DOI: 10.1016/j.reth.2020.03.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
6 Qin T, Fu J, Verkade HJ. The role of the gut microbiome in graft fibrosis after pediatric liver transplantation. Hum Genet 2021;140:709-24. [PMID: 32920649 DOI: 10.1007/s00439-020-02221-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Tokuhara D. Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents. Front Nutr 2021;8:700058. [PMID: 34250000 DOI: 10.3389/fnut.2021.700058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Gao B, Chi L, Zhu Y, Shi X, Tu P, Li B, Yin J, Gao N, Shen W, Schnabl B. An Introduction to Next Generation Sequencing Bioinformatic Analysis in Gut Microbiome Studies. Biomolecules 2021;11:530. [PMID: 33918473 DOI: 10.3390/biom11040530] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Tsai MC, Liu YY, Lin CC, Wang CC, Wu YJ, Yong CC, Chen KD, Chuah SK, Yao CC, Huang PY, Chen CH, Hu TH, Chen CL. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan. Nutrients 2020;12:E820. [PMID: 32204538 DOI: 10.3390/nu12030820] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
10 Chen D, Le TH, Shahidipour H, Read SA, Ahlenstiel G. The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression. Cells 2019;8:E1324. [PMID: 31717860 DOI: 10.3390/cells8111324] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
11 Monga Kravetz A, Testerman T, Galuppo B, Graf J, Pierpont B, Siebel S, Feinn R, Santoro N. Effect of Gut Microbiota and PNPLA3 rs738409 Variant on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Youth. J Clin Endocrinol Metab 2020;105:dgaa382. [PMID: 32561908 DOI: 10.1210/clinem/dgaa382] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
12 Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res 2021;7:11. [PMID: 33490737 DOI: 10.20517/2394-5079.2020.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Chen J, Vitetta L. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. Int J Mol Sci 2020;21:E5214. [PMID: 32717871 DOI: 10.3390/ijms21155214] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
14 Hoozemans J, de Brauw M, Nieuwdorp M, Gerdes V. Gut Microbiome and Metabolites in Patients with NAFLD and after Bariatric Surgery: A Comprehensive Review. Metabolites 2021;11:353. [PMID: 34072995 DOI: 10.3390/metabo11060353] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ko JS. New Perspectives in Pediatric Nonalcoholic Fatty Liver Disease: Epidemiology, Genetics, Diagnosis, and Natural History. Pediatr Gastroenterol Hepatol Nutr 2019;22:501-10. [PMID: 31777715 DOI: 10.5223/pghn.2019.22.6.501] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
16 Plaza-Díaz J, Solís-Urra P, Rodríguez-Rodríguez F, Olivares-Arancibia J, Navarro-Oliveros M, Abadía-Molina F, Álvarez-Mercado AI. The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage. Int J Mol Sci 2020;21:E8351. [PMID: 33171747 DOI: 10.3390/ijms21218351] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
17 Khan A, Ding Z, Ishaq M, Bacha AS, Khan I, Hanif A, Li W, Guo X. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates. Int J Biol Sci 2021;17:818-33. [PMID: 33767591 DOI: 10.7150/ijbs.56214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
18 Gui QF, Jin HL, Zhu F, Lu HF, Zhang Q, Xu J, Yang YM, Xiao C. Gut microbiota signatures in Schistosoma japonicum infection-induced liver cirrhosis patients: a case-control study. Infect Dis Poverty 2021;10:43. [PMID: 33771232 DOI: 10.1186/s40249-021-00821-8] [Reference Citation Analysis]
19 Hartmann P, Schnabl B. New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2021;41:87-102. [PMID: 33957682 DOI: 10.1055/s-0040-1719174] [Reference Citation Analysis]
20 Imai J, Kitamoto S, Kamada N. The pathogenic oral-gut-liver axis: new understandings and clinical implications. Expert Rev Clin Immunol 2021;17:727-36. [PMID: 34057877 DOI: 10.1080/1744666X.2021.1935877] [Reference Citation Analysis]
21 He LH, Yao DH, Wang LY, Zhang L, Bai XL. Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease. Front Microbiol 2021;12:761836. [PMID: 34795655 DOI: 10.3389/fmicb.2021.761836] [Reference Citation Analysis]
22 Fan C, Zhang L, Fu H, Liu C, Li W, Cheng Q, Zhang H, Jia S, Zhang Y. Enterotypes of the Gut Microbial Community and Their Response to Plant Secondary Compounds in Plateau Pikas. Microorganisms 2020;8:E1311. [PMID: 32872148 DOI: 10.3390/microorganisms8091311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
23 Abenavoli L, Falalyeyeva T, Pellicano R, Fagoonee S, Kobyliak N. Next generation of strain specific probiotics in diabetes treatment: the case of Prevotella copri. Minerva Endocrinol 2020;45:277-9. [PMID: 33213123 DOI: 10.23736/S0391-1977.20.03376-3] [Reference Citation Analysis]
24 Pan X, Kaminga AC, Liu A, Wen SW, Luo M, Luo J. Gut Microbiota, Glucose, Lipid, and Water-Electrolyte Metabolism in Children With Nonalcoholic Fatty Liver Disease. Front Cell Infect Microbiol 2021;11:683743. [PMID: 34778099 DOI: 10.3389/fcimb.2021.683743] [Reference Citation Analysis]
25 Witjes JJ, Smits LP, Pekmez CT, Prodan A, Meijnikman AS, Troelstra MA, Bouter KEC, Herrema H, Levin E, Holleboom AG, Winkelmeijer M, Beuers UH, van Lienden K, Aron-Wisnewky J, Mannisto V, Bergman JJ, Runge JH, Nederveen AJ, Dragsted LO, Konstanti P, Zoetendal EG, de Vos W, Verheij J, Groen AK, Nieuwdorp M. Donor Fecal Microbiota Transplantation Alters Gut Microbiota and Metabolites in Obese Individuals With Steatohepatitis. Hepatol Commun 2020;4:1578-90. [PMID: 33163830 DOI: 10.1002/hep4.1601] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
26 Su H, Liu J, Wu G, Long Z, Fan J, Xu Z, Liu J, Yu Z, Cao M, Liao N, Peng J, Yu W, Li W, Wu H, Wang X. Homeostasis of gut microbiota protects against polychlorinated biphenyl 126-induced metabolic dysfunction in liver of mice. Science of The Total Environment 2020;720:137597. [DOI: 10.1016/j.scitotenv.2020.137597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Kountouras J, Papaefthymiou A, Polyzos SA, Deretzi G, Vardaka E, Soteriades ES, Tzitiridou-Chatzopoulou M, Gkolfakis P, Karafyllidou K, Doulberis M. Impact of Helicobacter pylori-Related Metabolic Syndrome Parameters on Arterial Hypertension. Microorganisms 2021;9:2351. [PMID: 34835476 DOI: 10.3390/microorganisms9112351] [Reference Citation Analysis]
28 Jennison E, Byrne CD. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin Mol Hepatol 2021;27:22-43. [PMID: 33291863 DOI: 10.3350/cmh.2020.0129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
29 Choudhry H. The Microbiome and Its Implications in Cancer Immunotherapy. Molecules 2021;26:E206. [PMID: 33401586 DOI: 10.3390/molecules26010206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Castillo-Leon E, Cioffi CE, Vos MB. Perspectives on youth-onset nonalcoholic fatty liver disease. Endocrinol Diabetes Metab 2020;3:e00184. [PMID: 33102800 DOI: 10.1002/edm2.184] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
31 Houttu V, Boulund U, Grefhorst A, Soeters MR, Pinto-Sietsma SJ, Nieuwdorp M, Holleboom AG. The role of the gut microbiome and exercise in non-alcoholic fatty liver disease. Therap Adv Gastroenterol 2020;13:1756284820941745. [PMID: 32973925 DOI: 10.1177/1756284820941745] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Traversi D, Pulliero A, Izzotti A, Franchitti E, Iacoviello L, Gianfagna F, Gialluisi A, Izzi B, Agodi A, Barchitta M, Calabrò GE, Hoxhaj I, Sassano M, Sbrogiò LG, Del Sole A, Marchiori F, Pitini E, Migliara G, Marzuillo C, De Vito C, Tamburro M, Sammarco ML, Ripabelli G, Villari P, Boccia S. Precision Medicine and Public Health: New Challenges for Effective and Sustainable Health. J Pers Med 2021;11:135. [PMID: 33669364 DOI: 10.3390/jpm11020135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Chen L, Zhang L, Wang W, Qiu W, Liu L, Ning A, Cao J, Huang M, Zhong M. Polysaccharides isolated from Cordyceps Sinensis contribute to the progression of NASH by modifying the gut microbiota in mice fed a high-fat diet. PLoS One 2020;15:e0232972. [PMID: 32512581 DOI: 10.1371/journal.pone.0232972] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
34 Zhao T, Zhan L, Zhou W, Chen W, Luo J, Zhang L, Weng Z, Zhao C, Liu S. The Effects of Erchen Decoction on Gut Microbiota and Lipid Metabolism Disorders in Zucker Diabetic Fatty Rats. Front Pharmacol 2021;12:647529. [PMID: 34366839 DOI: 10.3389/fphar.2021.647529] [Reference Citation Analysis]
35 Fianchi F, Liguori A, Gasbarrini A, Grieco A, Miele L. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. Int J Mol Sci 2021;22:6485. [PMID: 34204274 DOI: 10.3390/ijms22126485] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Satapathy SK, Banerjee P, Pierre JF, Higgins D, Dutta S, Heda R, Khan SD, Mupparaju VK, Mas V, Nair S, Eason JD, Kleiner DE, Maluf DG. Characterization of Gut Microbiome in Liver Transplant Recipients With Nonalcoholic Steatohepatitis. Transplant Direct 2020;6:e625. [PMID: 33204823 DOI: 10.1097/TXD.0000000000001033] [Reference Citation Analysis]
37 Shaunak M, Byrne CD, Davis N, Afolabi P, Faust SN, Davies JH. Non-alcoholic fatty liver disease and childhood obesity.Arch Dis Child. 2021;106:3-8. [PMID: 32409495 DOI: 10.1136/archdischild-2019-318063] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
38 Mandala A, Janssen RC, Palle S, Short KR, Friedman JE. Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms. Nutrients 2020;12:E3166. [PMID: 33081177 DOI: 10.3390/nu12103166] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
39 Kanda T, Goto T, Hirotsu Y, Masuzaki R, Moriyama M, Omata M. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E1525. [PMID: 32102237 DOI: 10.3390/ijms21041525] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
40 Vittorio J, Lavine JE. Recent advances in understanding and managing pediatric nonalcoholic fatty liver disease. F1000Res 2020;9:F1000 Faculty Rev-377. [PMID: 32509277 DOI: 10.12688/f1000research.24198.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
41 Pyo JH, Kim TJ, Lee H, Choi SC, Cho SJ, Choi YH, Min YW, Min BH, Lee JH, Kang M, Lee YC, Kim JJ. Proton pump inhibitors use and the risk of fatty liver disease: A nationwide cohort study. J Gastroenterol Hepatol 2021;36:1235-43. [PMID: 32886822 DOI: 10.1111/jgh.15236] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Vancells Lujan P, Viñas Esmel E, Sacanella Meseguer E. Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. Nutrients 2021;13:1442. [PMID: 33923255 DOI: 10.3390/nu13051442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021;184:2537-64. [PMID: 33989548 DOI: 10.1016/j.cell.2021.04.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
44 Yu EL, Schwimmer JB. Epidemiology of Pediatric Nonalcoholic Fatty Liver Disease. Clin Liver Dis (Hoboken) 2021;17:196-9. [PMID: 33868665 DOI: 10.1002/cld.1027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Francescangeli F, De Angelis ML, Zeuner A. Dietary Factors in the Control of Gut Homeostasis, Intestinal Stem Cells, and Colorectal Cancer. Nutrients 2019;11:E2936. [PMID: 31816977 DOI: 10.3390/nu11122936] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
46 Wu J, Wang K, Wang X, Pang Y, Jiang C. The role of the gut microbiome and its metabolites in metabolic diseases. Protein Cell 2021;12:360-73. [PMID: 33346905 DOI: 10.1007/s13238-020-00814-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
47 Mouzaki M, Loomba R. An update on the role of the microbiome in non-alcoholic fatty liver disease pathogenesis, diagnosis, and treatment. Curr Treat Options Gastroenterol 2020;18:270-80. [PMID: 33716495 DOI: 10.1007/s11938-020-00290-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Jiang Y, Chowdhury S, Xu BH, Meybodi MA, Damiris K, Devalaraju S, Pyrsopoulos N. Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection. World J Hepatol 2021; 13(11): 1777-1790 [PMID: 34904045 DOI: 10.4254/wjh.v13.i11.1777] [Reference Citation Analysis]
49 Sookoian S, Salatino A, Castaño GO, Landa MS, Fijalkowky C, Garaycoechea M, Pirola CJ. Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. Gut 2020;69:1483-91. [DOI: 10.1136/gutjnl-2019-318811] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 17.5] [Reference Citation Analysis]
50 Wang P, Dong Y, Zuo K, Han C, Jiao J, Yang X, Li J. Characteristics and variation of fecal bacterial communities and functions in isolated systolic and diastolic hypertensive patients. BMC Microbiol 2021;21:128. [PMID: 33902467 DOI: 10.1186/s12866-021-02195-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Li H, Hu Y. Intestinal Microecology: An Important Target for Chinese Medicine Treatment of Non-alcoholic Fatty Liver Disease. Chin J Integr Med 2020;26:723-8. [DOI: 10.1007/s11655-020-3268-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
52 Kordy K, Li F, Lee DJ, Kinchen JM, Jew MH, La Rocque ME, Zabih S, Saavedra M, Woodward C, Cunningham NJ, Tobin NH, Aldrovandi GM. Metabolomic Predictors of Non-alcoholic Steatohepatitis and Advanced Fibrosis in Children. Front Microbiol 2021;12:713234. [PMID: 34475864 DOI: 10.3389/fmicb.2021.713234] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Samji NS, Heda R, Kovalic AJ, Satapathy SK. Similarities and Differences Between Nonalcoholic Steatohepatitis and Other Causes of Cirrhosis. Gastroenterology Clinics of North America 2020;49:151-64. [DOI: 10.1016/j.gtc.2019.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Houttu V, Csader S, Nieuwdorp M, Holleboom AG, Schwab U. Dietary Interventions in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Nutr 2021;8:716783. [PMID: 34368214 DOI: 10.3389/fnut.2021.716783] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Guo Q, Tang Y, Li Y, Xu Z, Zhang D, Liu J, Wang X, Xia W, Xu S. Perinatal High-Salt Diet Induces Gut Microbiota Dysbiosis, Bile Acid Homeostasis Disbalance, and NAFLD in Weanling Mice Offspring. Nutrients 2021;13:2135. [PMID: 34206629 DOI: 10.3390/nu13072135] [Reference Citation Analysis]
56 Goldner D, Lavine JE. Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges. Gastroenterology. 2020;158:1967-1983.e1. [PMID: 32201176 DOI: 10.1053/j.gastro.2020.01.048] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
57 Almeida JI, Tenreiro MF, Martinez-Santamaria L, Aspizua SG, Gisbert JP, Alves PM, Serra M, Baptista PM. Hallmarks of the human intestinal microbiome on liver maturation and function. J Hepatol 2021:S0168-8278(21)02152-8. [PMID: 34715263 DOI: 10.1016/j.jhep.2021.10.015] [Reference Citation Analysis]
58 Goeser F, Münch P, Lesker TR, Lutz PL, Krämer B, Kaczmarek DJ, Finnemann C, Nischalke HD, Geffers R, Parcina M, McHardy A, Strassburg C, Hoerauf A, Nattermann J, Bekeredjian-Ding I, Spengler U. Neither black nor white: do altered intestinal microbiota reflect chronic liver disease severity? Gut 2021;70:438-40. [PMID: 32503844 DOI: 10.1136/gutjnl-2020-321424] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Zhao Y, Zhao G, Chen Z, She Z, Cai J, Li H. Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension. Hypertension 2020;75:275-84. [DOI: 10.1161/hypertensionaha.119.13419] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 10.5] [Reference Citation Analysis]
60 Sookoian S, Pirola CJ. Liver tissue microbiota in nonalcoholic liver disease: a change in the paradigm of host-bacterial interactions. Hepatobiliary Surg Nutr 2021;10:337-49. [PMID: 34159161 DOI: 10.21037/hbsn-20-270] [Reference Citation Analysis]
61 Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of Insulin Resistance in MAFLD. Int J Mol Sci 2021;22:4156. [PMID: 33923817 DOI: 10.3390/ijms22084156] [Reference Citation Analysis]
62 Fu H, Zhang L, Fan C, Liu C, Li W, Li J, Zhao X, Jia S, Zhang Y. Domestication Shapes the Community Structure and Functional Metagenomic Content of the Yak Fecal Microbiota. Front Microbiol 2021;12:594075. [PMID: 33897627 DOI: 10.3389/fmicb.2021.594075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Salzman NH, Schwimmer JB. Pediatric nonalcoholic fatty liver disease and the microbiome: Mechanisms contributing to pathogenesis and progression. Curr Opin Endocr Metab Res 2021;19:22-9. [PMID: 34222711 DOI: 10.1016/j.coemr.2021.05.003] [Reference Citation Analysis]
64 Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2021;69:1691-705. [DOI: 10.1136/gutjnl-2020-320622] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 26.5] [Reference Citation Analysis]
65 Hu Y, He J, Zheng P, Mao X, Huang Z, Yan H, Luo Y, Yu J, Luo J, Yu B, Chen D. Prebiotic inulin as a treatment of obesity related nonalcoholic fatty liver disease through gut microbiota: a critical review. Crit Rev Food Sci Nutr 2021;:1-11. [PMID: 34292103 DOI: 10.1080/10408398.2021.1955654] [Reference Citation Analysis]
66 Alemán JO, Henderson WA, Walker JM, Ronning A, Jones DR, Walter PJ, Daniel SG, Bittinger K, Vaughan R, MacArthur R, Chen K, Breslow JL, Holt PR. Excess dietary fructose does not alter gut microbiota or permeability in humans: A pilot randomized controlled study. J Clin Transl Sci 2021;5:e143. [PMID: 34422323 DOI: 10.1017/cts.2021.801] [Reference Citation Analysis]
67 Crudele A, Panera N, Braghini MR, Balsano C, Alisi A. The pharmacological treatment of nonalcoholic fatty liver disease in children. Expert Rev Clin Pharmacol 2020;13:1219-27. [PMID: 32981386 DOI: 10.1080/17512433.2020.1829468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]